Latest news
Vistagen reports exploratory Phase II miss for social anxiety drug candidate - AllSciAllSci · Fri, 07 Aug 2026 14:39:45 GMTVistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study - PharmaLivePharmaLive · Fri, 07 Aug 2026 13:10:50 GMTVistaGen Granted Nasdaq Extension to Regain Bid Compliance - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 21:06:00 GMTVistagen (VTGN) Reports Phase 2 Social Anxiety Study Results Ami - GuruFocusGuruFocus · Thu, 06 Aug 2026 15:59:51 GMTDouble shot of Vistagen’s anxiety nasal spray misses in ph. 2 - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 14:32:35 GMTVistagen's second fasedienol dose showed no new safety findings - Stock TitanStock Titan · Thu, 06 Aug 2026 12:30:00 GMTVistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Yahoo Finance SingaporeYahoo Finance Singapore · Thu, 06 Aug 2026 12:30:00 GMTVistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension - Stock TitanStock Titan · Wed, 05 Aug 2026 20:05:55 GMT